布洛芬,其他NSAIDs和COVID-19:一个叙事审查
William Laughey1,2, Imran Lodhi3, Graham Pennick3
1Reckitt Health Care UK Ltd, Hull, UK. bill.laughey@reckitt.com.
Inflammopharmacology
|August 21, 2023
概括
像布洛芬这样的非类固醇抗炎药 (NSAIDs) 不会增加COVID-19的易感性或恶化结果. 有证据表明,NSAIDs对于控制症状是安全的,并且不会影响疫苗反应.
科学领域:
- 药理学 药理学是指药理学的学科.
- 传染性疾病 传染性疾病
- 公共卫生 公共卫生
背景情况:
- 在COVID-19大流行初期,人们对NSAID安全性产生了担忧.
- 猜测表明,包括布洛芬在内的NSAID可能会增加SARS-CoV-2的易感性,并加剧COVID-19的结果.
- 这导致了混乱,并导致了COVID-19的"传染病".
研究的目的:
- 审查和综合有关在COVID-19中NSAID使用的证据.
- 澄清NSAIDs对感染,疾病进展和疫苗反应的安全性和影响.
主要方法:
- 在体外和体内研究的叙述性综述.
- 对观察性研究,系统审查和元分析的分析.
- 评估NSAID对SARS-CoV-2易感性,临床结果和疫苗免疫力的影响.
主要成果:
- 绝大多数证据表明,NSAIDs不会增加对SARS-CoV-2感染的易感性.
- 使用NSAID与COVID-19患者的临床结果恶化无关.
- 无 NSAIDs 不会对 COVID-19 疫苗的免疫反应产生负面影响.
结论:
- 没有科学依据限制NSAIDs用于COVID-19症状管理的使用.
- 限制NSAID的使用可能会阻碍患者有效自我护理.
- 在COVID-19期间,NSAID仍然是缓解症状的安全和有效选择.
相关概念视频
Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents
246
Diarrhea, a condition marked by frequent loose or watery bowel movements, can be triggered by multiple factors such as viral or bacterial infections, food intolerances, anxiety, medications, and digestive disorders. Symptoms may include abdominal pain, bloating, nausea, and cramping. Severe or prolonged diarrhea can lead to complications like electrolyte imbalances, malnutrition, and dehydration if left untreated.
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
246
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
495
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
495
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Inflammatory Bowel Disease IV: Pharmacological Management
152
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
152
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
516
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
516
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
562
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
562


